RecruitingNCT03318406

Post-Market BTVA Registry

Post-Market Registry for Patients With Emphysema Treated With BTVA

Sponsor

Uptake Medical Technology, Inc.

Enrollment

300 participants

Start Date

Mar 22, 2018

Study Type

OBSERVATIONAL

Conditions

Emphysema or COPD

Summary

Bronchoscopic thermal vapor ablation using Uptake Medical Technology Inc.'s InterVapor System is indicated for treatment of patients with heterogeneous upper lobe emphysema. This study is a retrospective and prospective, observational, multi-center, post-market registry of patients prescribed InterVapor. The primary objective of the Registry is to describe the long-term impact of InterVapor treatment on patient quality of life (QOL) in a real-world setting. After InterVapor treatment, patients will be followed for 5 years as per the standard of care and safety and efficacy data (quality of life, pulmonary function, exercise capacity) collected as part of the registry.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This registry study is tracking patients who have received a bronchoscopic procedure called BTVA (bronchoscopic thermal vapour ablation) — a minimally invasive treatment that reduces damaged areas of the lungs — in people with a condition called heterogeneous emphysema, where some parts of the lung are more damaged than others. **You may be eligible if...** - You are 18 years old or older - You have heterogeneous emphysema confirmed by a high-resolution CT scan - You have received or are about to receive the BTVA lung treatment - You are willing to participate and sign consent **You may NOT be eligible if...** - Your emphysema is uniform throughout the lung (not heterogeneous) - You are under 18 years old - You are unwilling to give consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEBronchoscopic Thermal Vapor Ablation

Bronchoscopic vapor delivery to airway segment(s) targeted for treatment

Locations(20)

Krankenhaus Nord - Klinik Floridsdorf

Vienna, Austria

Sozialstiftung Bamberg, Klinikum am Bruderwald

Bamberg, Germany

DRK Kliniken Berlin / Mitte

Berlin, Germany

FORSCHUNGSINSTITUT Havelhöhe gGmbH

Berlin, Germany

Ruhrlandklinik - Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH

Essen, Germany

Asklepios Fachkliniken München-Gauting

Gauting, Germany

Martin-Luther-Universität Halle-Wittenberg (Saale)

Halle, Germany

Thoraxklinik Heidelberg

Heidelberg, Germany

Lungenklinik Hemer

Hemer, Germany

Lungenfachklinik Immenhausen

Immenhausen, Germany

Krankenhaus Martha-Maria München

München, Germany

Klinikum Nürnberg Nord

Nuremberg, Germany

Krankenhaus vom Roten Kreuz Bad Cannstatt GmbH

Stuttgart, Germany

Klinik Schillerhöhe

Stuttgart, Germany

Kantonsspital Aarau AG

Aarau, Switzerland

University Hospital Basel

Basel, Switzerland

Lungen-und Schlafzentrum am Lindenhofspital AG, Bern

Bern, Switzerland

Kantonsspital St.Gallen

Sankt Gallen, Switzerland

LungenZentrum Hirslanden

Zurich, Switzerland

Universitäts Spital Zürich

Zurich, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03318406

Related Trials

Combined Zephyr Valve System With Inter-lobar Fissure Completion for Lung Volume Reduction in Emphysema

NCT048011081 location

Inter-lobar Fissure Completion in Patients With Failed Bronchoscopic Lung Volume Reduction

NCT052576811 location

An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema

NCT0603512036 locations

PiMZ Longitudinal Cohort (PiMZ Logic)

NCT065056035 locations

Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure

NCT035007312 locations